Oramed Pharmaceuticals (NASDAQ:ORMP) versus Akanda (NASDAQ:AKAN) Head-To-Head Analysis

Akanda (NASDAQ:AKAN) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Akanda and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Akanda	N/A	N/A	N/A
Oramed Pharmaceuticals	N/A	-6.83%	-6.25%

Institutional and Insider Ownership

1.0% of Akanda shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 20.4% of Akanda shares are owned by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Akanda has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Akanda and Oramed Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akanda	1	0	0	0	1.00
Oramed Pharmaceuticals	0	1	0	0	2.00

Valuation & Earnings

This table compares Akanda and Oramed Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akanda	$840,000.00	1.97	-$4.10 million	N/A	N/A
Oramed Pharmaceuticals	$2.00 million	68.56	$64.05 million	$1.49	2.28

Oramed Pharmaceuticals has higher revenue and earnings than Akanda.

Summary

Oramed Pharmaceuticals beats Akanda on 5 of the 9 factors compared between the two stocks.

About Akanda

Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.